Pharmalittle: We’re reading about Prasad leaving FDA, a pause on NIH spending, and much more
Vinay Prasad, a top FDA official, suddenly departed after a series of controversial decisions about a Duchenne gene therapy and criticism from conservatives
Related Articles
Trump escalates demands that pharma companies lower their drug prices
Trump demanded that pharmaceutical companies lower their drug prices. But it’s unclear how the government may enforce the directive.
Senate committee endorses NIH budget increase, rebuking Trump administration’s proposed 40% cut
Senators from both parties endorsed a $400 million increase to the budget of the National Institutes of Health on Thursday
AIDS activists sue HHS to obtain Gilead settlement over patents for HIV prevention pills
An advocacy group is suing the Trump administration for failing to disclose details of a settlement with Gilead over patent rights to HIV prevention pills
Representatives of expert groups to be barred from work supporting CDC’s vaccine advisers
The reshaping of the CDC’s vaccine advisory panel has continued, with the apparent barring of reps of medical associations from ACIP work groups.
AIDS activists sue HHS to obtain Gilead settlement over patents for HIV prevention pills
An advocacy group is suing the Trump administration for failing to disclose details of a settlement with Gilead over patent rights to HIV prevention pills
AIDS activists sue HHS to obtain Gilead settlement over patents for HIV prevention pills
An advocacy group is suing the Trump administration for failing to disclose details of a settlement with Gilead over patent rights to HIV prevention pills
Senate committee endorses NIH budget increase, rebuking Trump administration’s proposed 40% cut
Senators from both parties endorsed a $400 million increase to the budget of the National Institutes of Health on Thursday
AIDS activists sue HHS to obtain Gilead settlement over patents for HIV prevention pills
An advocacy group is suing the Trump administration for failing to disclose details of a settlement with Gilead over patent rights to HIV prevention pills
Up and down the ladder: The latest comings and goings
From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
Vinay Prasad is my former student and friend. His departure from FDA is a loss for American medicine
“It is hard to imagine someone more equipped and more dedicated to vetting treatments than Vinay Prasad,” writes his former professor and friend Adam Cifu.